Anne-Marie Li-Kwai-Cheung, MChem, MTOPRA, RAPS

Title: Chief Development Officer

Organization: Wave Life Sciences

CureDuchenne Webinar with Wave Life Sciences

Wave will provide an overview of initial clinical trial results for WVE-N531 in individuals with Duchenne muscular dystrophy who are amenable to exon 53 skipping, as well as an overview of the potentially registrational FORWARD-53 study. 

Anne-Marie Li-Kwai-Cheung, MChem, MTOPRA, RAPS

Chief Development Officer

Wave Life Sciences

See more from same speaker

Michael Kelly, PhD

Chief Scientific Advisor

CureDuchenne

See more from same speaker

Video
Share this:
Beginning the Journey - diagnosed 0-3 yearsGrowth and Transformation - diagnosed 3-6 yearsSpreading Wisdom - diagnosed 6+ years